Utility of circulating tumor DNA for predicting prognosis in the management of resectable pancreatic cancer

被引：0
|
作者：
Tyerman, Zachary [1 ]
Ambler, Emily [2 ]
Schlick, Cary Jo R. [1 ]
Nwajei, Felix [4 ]
Chawla, Akhil [1 ,2 ,3 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA
[2] Northwestern Univ, Div Surg Oncol, Dept Surg, Northwestern Med Reg Med Grp,Feinberg Sch Med, Chicago, IL 60190 USA
[3] Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[4] Duke Univ, Sch Med, Dept Neurol, Durham, NC 27710 USA
来源：
JOURNAL OF CANCER METASTASIS AND TREATMENT | 2022年 / 8卷
关键词：
Pancreatic cancer; circulating tumor DNA; prognosis; survival; DUCTAL ADENOCARCINOMA; DIAGNOSIS; MARKER; RESISTANCE; MUTATIONS; CA19-9; PLASMA; BLOOD; SERUM;
D O I：
10.20517/2394-4722.2022.20
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: The measurement of circulating tumor DNA (ctDNA) has been studied in several malignancies, including metastatic pancreatic cancer, but less is known about its utility in monitoring treatment response and recurrence in resectable pancreatic cancer. Methods: We conducted a systematic review of the literature examining the association of ctDNA with overall survival (OS) and disease-free survival. Results: Five articles met our exclusion criteria. Baseline and/or postoperative ctDNA was found to be associated with decreased OS and recurrence-free survival. Discussion: ctDNA has the potential to be used as a prognostic biomarker and to guide therapy in resectable pancreatic cancer.
引用
收藏
页数：9
相关论文
共 50 条
  • [1] Clinical utility of circulating tumor DNA in resectable and advanced pancreatic cancer
    Popova, A.
    Fedyanin, M.
    Pokataev, I.
    Shamovskaya, D.
    Kudashkin, N.
    Boyarskikh, U.
    Kechin, A.
    Oscorbin, I.
    Moroz, E.
    Trigolosov, A.
    Filipenko, M.
    Podluzhnyi, D.
    Tjulandin, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S180 - S181
  • [2] LEClinical Utility of Comprehensive Sequencing of Circulating Tumor DNA in Resectable Pancreatic Cancer
    Imamura, Taisuke
    Ashida, Ryo
    Sugiura, Teiichi
    Ohgi, Katsuhisa
    Yamada, Mihoko
    Otsuka, Shimpei
    Uesaka, Katsuhiko
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2023, 237 (05) : S285 - S285
  • [3] Clinical Utility of Pancreatic Cancer Circulating Tumor DNA in Predicting Disease Progression, Prognosis, and Response to Chemotherapy
    Takada, Ryoji
    Ohkawa, Kazuyoshi
    Kukita, Yoji
    Ikezawa, Kenji
    Fukutake, Nobuyasu
    Abe, Yutaro
    Imai, Toshihiro
    Kiyota, Ryosuke
    Nawa, Takatoshi
    Yamai, Takuo
    Ashida, Reiko
    Kato, Kikuya
    Katayama, Kazuhiro
    PANCREAS, 2020, 49 (09) : E93 - E95
  • [4] Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer
    Eckhoff, Austin
    Kanu, Elishama
    Fletcher, Ashley
    Bao, Matthew
    Nussbaum, Daniel P.
    Blazer, Dan G., III
    Lidsky, Michael E.
    Zani, Sabino
    Shah, Kevin
    Aushev, Vasily
    Krinshpun, Shifra
    Jurdi, Adham
    Liu, Minetta
    Allen, Peter J.
    Herbert, Garth
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S76 - S76
  • [5] Clinical utility of circulating tumor DNA (ctDNA) in resectable pancreatic ductal adenocarcinoma (PDAC)
    Wong, Hui -Li
    Bushell, Kevin
    Karasinska, Joanna
    Arthur, Sarah
    Morin, Ryan
    Schaeffer, David F.
    Renouf, Daniel John
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Clinical utility of circulating tumor DNA (ctDNA) in resectable pancreatic ductal adenocarcinoma (PDAC)
    Wong, Hui-Li
    Bushell, Kevin
    Karasinska, Joanna
    Arthur, Sarah
    Morin, Ryan
    Schaeffer, David F.
    Renouf, Daniel John
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [7] Serial circulating tumor DNA monitoring for predicting treatment response and prognosis in patients with pancreatic cancer
    Lee, Jongchan
    Ahn, Jinwoo
    Jung, Kwangrok
    Lee, Jong-Chan
    Youn, Yuna
    Hwang, Jin-Hyeok
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Clinical utility of circulating tumor DNA (ctDNA) n resectable pancreatic ductal adenocarcinoma (PDAC)
    Wong, H-L.
    Bushell, K.
    Karasinska, J.
    Arthur, S.
    Pararajalingam, P.
    Morin, R.
    Schaeffer, D. F.
    Renouf, D. J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer
    Erina Takai
    Yasushi Totoki
    Hiromi Nakamura
    Chigusa Morizane
    Satoshi Nara
    Natsuko Hama
    Masami Suzuki
    Eisaku Furukawa
    Mamoru Kato
    Hideyuki Hayashi
    Takashi Kohno
    Hideki Ueno
    Kazuaki Shimada
    Takuji Okusaka
    Hitoshi Nakagama
    Tatsuhiro Shibata
    Shinichi Yachida
    Scientific Reports, 5
  • [10] Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer
    Takai, Erina
    Totoki, Yasushi
    Nakamura, Hiromi
    Morizane, Chigusa
    Nara, Satoshi
    Hama, Natsuko
    Suzuki, Masami
    Furukawa, Eisaku
    Kato, Mamoru
    Hayashi, Hideyuki
    Kohno, Takashi
    Ueno, Hideki
    Shimada, Kazuaki
    Okusaka, Takuji
    Nakagama, Hitoshi
    Shibata, Tatsuhiro
    Yachida, Shinichi
    SCIENTIFIC REPORTS, 2015, 5
12345